(b)(4).Investigation summary: one photo was provided for evaluation.It shows a packaging box label with 50ml and a packaging blister of a 60ml.Both products are labeled as catalog# 309620.Based on a business decision, the 60ml syringe was phased out, and the 50ml introduced replacing the 60ml.The hypodermic platform team confirmed to keep the same catalog# for both products.Based on the investigation and with the photo provided, the symptom reported by the customer is confirmed.Both products comply with the specifications at the time of each production.The 60ml is no longer produced, only 50ml.A device history record review was completed with zero defects found.No quality notifications were written for this batch, nor for the associated assembly batches.Trend analysis has shown that this is the only complaint received for this condition and lot number.As such, it appears that the sample shown in the photo provided is likely due to an isolated occurrence.No further action seems to be warranted at this time.Complaints received for this device and reported condition would continue to be tracked and trended.Information will be captured on trend reports and monitored monthly.Our business team regularly reviews the collected data for the identification of emerging trends.Investigation conclusion: this is the 1st complaint for lot # 0052176 for this type of defect or symptom.There was no documentation for this type of defect during the entire production run of this batch.Based on the investigation and with the photo provided, the symptom reported by the customer is confirmed.Both products comply with the specifications at the time of each production.The 60ml is no longer produced, only 50ml.Rationale: capa not required at this time.
|